Sign up USA
Proactive Investors - Run By Investors For Investors

Akers Biosciences Inc breakthrough device granted US patent

The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.
Stylised picture of patent agreement plus padlock.
The US Patent and Trademark Offices has given its sign-off.

Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin.

The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.

"This patent is particularly important because it protects the antigen that gives our tests their superior accuracy,” said chairman and co-founder Raymond Akers.

“With published studies that demonstrate that our tests never deliver a false positive result, we believe them to be the most accurate available way to rule out HIT."

The device takes 10 minutes to assess for heparin-induced thrombocytopenia, or HIT, where the blood clots instead of thins.

The process of assessing a patient for HIT requires expensive blood tests that can take several days to turn around.

The diagnostic is the only one of its kind to receive sign off from America’s all-powerful Food & Drug Administration.

Ian_55ae0ddd437b7.jpg
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future AKR Company articles
View full AKR profile

Akers Biosciences, Inc. Timeline

Article
August 11 2016

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
AZN3.jpg
November 10 2016
Patent safeguards the technology at the heart of the device that offers a non-invasive method of monitoring diabetes.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC